No current positioning snapshot.
Current snapshotPublic companyResearch currentFresh
Hyperfine, Inc.
Intervene · Healthspan Infrastructure
SignalWATCHReviewed 25 Oct 2026
Intervene exposure in Healthspan Infrastructure.
Hyperfine sells portable low-field MRI systems designed for bedside/brain imaging
Catalysts
Preliminary Q3 2026 revenue ~$6.0M (record), 9M ~$13.8M, cash ~$37.9M at 9/30/26; FY2026 revenue outlook ~$20-22M reaffirmed (8-K 2.02/7.01 10-08-26). Nasdaq minimum-bid deficiency notice received 9-17-26 (closing bid <$1.00 for 30 consecutive days) - 180-day cure period, no immediate delisting effect (8-K 3.01).
Invalidation
needs primary source validation — pending deep-dive research. Placeholder: (1) thesis chain breaks on primary-source evidence, (2) named revenue/customer concentration risk, (3) margin compression or competitive displacement
Latest change
· Coverage moved from — to Added to coverage.
Capital in context
Mapped funds and investors
Direct relationships supported by published evidence.
Reported holdings as-of
No sourced relationships mapped yet.
Disclosed investment history
No sourced relationships mapped yet.
Showing up to four relationships in each group. ETF weights describe the fund’s portfolio, not ownership of this company. Private investment history does not establish current ownership.
needs primary source validation — no X/Reddit signal yet
Lower-confidence snapshotTarget price: $1.80
Dated research targetMoat & position
- Evidence Grade
- Inferred
- Toll Road Tier
- Strong proxy